董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nissim Darvish | 男 | Director | 57 | 未披露 | 未持股 | 2022-01-05 |
| Claude Nicaise | 男 | Director | 69 | 未披露 | 未持股 | 2022-01-05 |
| Alan Moses | 男 | Director | 74 | 未披露 | 未持股 | 2022-01-05 |
| Neil Cohen | 男 | Director | 58 | 未披露 | 未持股 | 2022-01-05 |
| Adi Mor | 女 | Director, Chief Scientific Officer | 40 | 未披露 | 未持股 | 2022-01-05 |
| Dale Pfost | 男 | Director, Chief Executive Officer and Chairman | 64 | 未披露 | 未持股 | 2022-01-05 |
| Joel Maryles | 男 | Director | 62 | 未披露 | 未持股 | 2022-01-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adi Mor | 女 | Director, Chief Scientific Officer | 40 | 未披露 | 未持股 | 2022-01-05 |
| Arnon Aharon | 男 | Outgoing Chief Medical Officer | 53 | 未披露 | 未持股 | 2022-01-05 |
| Dale Pfost | 男 | Director, Chief Executive Officer and Chairman | 64 | 未披露 | 未持股 | 2022-01-05 |
| Donald Marvin | 男 | Chief Financial Officer, Executive Vice President and Chief Operating Officer | 69 | 未披露 | 未持股 | 2022-01-05 |
董事简历
中英对照 | 中文 | 英文- Nissim Darvish
-
Nissim Darvish，2013年3月以来，一直担任Medigus有限公司董事长；2014年12月23日，他再次当选为董事、董事长，直到下届年度股东大会。他也是OrbiMed Advisors LLC的高级董事总经理。他现为下列企业的董事：Ornim Medical Inc., RDD Pharma Ltd., Otic Pharma Ltd., Tyto Care., Keystone Heart Ltd., OrbiMed Israel Partner Ltd., OrbiMed Israel Limited Partnership., Asdanit Medical Ltd., Asdan Medical Ltd. and Ramot，这是 Tel Aviv University's TAU 的技术转让公司。他曾担任Pitango VC的普通合伙人，该公司从事生命科学行业投资。他在以色列的The Technion Institute of Technology获得医学博士学位、理科博士学位、生物物理医学博士学位。随后在NIH进行博士后研究。发表专利100余项，发表著作20余篇。
Nissim Darvish has served on our board of directors since March 16 2021. Dr. Darvish is a General Partner at MeOhr Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several private companies. Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards of directors of 9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was a General Partner managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he culminated in a $250 million realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications. - Nissim Darvish，2013年3月以来，一直担任Medigus有限公司董事长；2014年12月23日，他再次当选为董事、董事长，直到下届年度股东大会。他也是OrbiMed Advisors LLC的高级董事总经理。他现为下列企业的董事：Ornim Medical Inc., RDD Pharma Ltd., Otic Pharma Ltd., Tyto Care., Keystone Heart Ltd., OrbiMed Israel Partner Ltd., OrbiMed Israel Limited Partnership., Asdanit Medical Ltd., Asdan Medical Ltd. and Ramot，这是 Tel Aviv University's TAU 的技术转让公司。他曾担任Pitango VC的普通合伙人，该公司从事生命科学行业投资。他在以色列的The Technion Institute of Technology获得医学博士学位、理科博士学位、生物物理医学博士学位。随后在NIH进行博士后研究。发表专利100余项，发表著作20余篇。
- Nissim Darvish has served on our board of directors since March 16 2021. Dr. Darvish is a General Partner at MeOhr Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several private companies. Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards of directors of 9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was a General Partner managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he culminated in a $250 million realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications.
- Claude Nicaise
-
Claude Nicaise，从2015年6月起在本公司担任董事会成员。他目前还担任我们薪酬委员会、研发委员会成员。Nicaise 博士是一家为生物技术公司提供临床和监管事项咨询公司-Clinical Regulatory Services的所有者。2008-2014年，在 Alexion Pharmaceuticals担任战略发展和全球监管事务高级副总裁。1983-2008，在 Bristol-Myers Squibb担任逐渐重要的各种职位，包括以下高级管理职位：全球发展副总裁、全球监管科学和战略副总裁，以及肿瘤、感染性疾病和神经科学发展领导职位。
Claude Nicaise has served on our board of directors since March 16 2021. Dr. Nicaise is a physician with extensive US and international experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Dr. Nicaise currently serves on the board of directors and as the Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. NASDAQ: SRPT, since 2015 as well as on the board of directors of Mynoryx Therapeutics, since 2017. Prior to that time, from 2008 to 2014 Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008 he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels University, Belgium. - Claude Nicaise，从2015年6月起在本公司担任董事会成员。他目前还担任我们薪酬委员会、研发委员会成员。Nicaise 博士是一家为生物技术公司提供临床和监管事项咨询公司-Clinical Regulatory Services的所有者。2008-2014年，在 Alexion Pharmaceuticals担任战略发展和全球监管事务高级副总裁。1983-2008，在 Bristol-Myers Squibb担任逐渐重要的各种职位，包括以下高级管理职位：全球发展副总裁、全球监管科学和战略副总裁，以及肿瘤、感染性疾病和神经科学发展领导职位。
- Claude Nicaise has served on our board of directors since March 16 2021. Dr. Nicaise is a physician with extensive US and international experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Dr. Nicaise currently serves on the board of directors and as the Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. NASDAQ: SRPT, since 2015 as well as on the board of directors of Mynoryx Therapeutics, since 2017. Prior to that time, from 2008 to 2014 Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008 he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels University, Belgium.
- Alan Moses
-
Alan Moses自2021年3月16日起担任我们的董事会成员。摩西博士是ABIM的董事会成员，并获得内分泌学和代谢方面的亚专科认证，并且是美国医师协会的会员。自2018年以来，摩西博士目前担任BioFabusa董事会成员。在此之前，Moses博士于2008年至2018年担任Novo NordiskA/SCPH:Novo-B的全球首席医疗官，他于2004年加入该公司。摩西博士于2002年至2006年担任哈佛医学院的医学教授，并与麻省理工学院合作，共同创立并共同指导了临床研究者培训计划，该计划专注于培训转化研究方面的医师-科学家。从1998年到2004年，Moses博士曾担任乔斯林糖尿病中心的高级副总裁兼首席医疗官。摩西博士拥有北卡罗来纳州杜克大学的学士学位和密苏里州华盛顿大学医学院的医学博士学位。
Alan Moses,has served as a director of the Company since October 2020. Dr. Moses has been a Board member of Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) since March 2021. Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S from 2013 until his retirement in 2018. Prior to that he served in various roles at Novo Nordisk A/S since 2004, beginning as Associate Vice President of Medical Affairs in the United States. Throughout his career, Dr. Moses has specialized in developing novel therapeutics and diagnostics for diabetes mellitus. He co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic, and has served as a member of the Board of Joslin Diabetes Center since December 2021. Dr. Moses also serves on two nonprofit boards as Chairman of the Board of the diaTribe Foundation and as a member of the Greater New England Chapter of the Juvenile Diabetes Research Association. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. - Alan Moses自2021年3月16日起担任我们的董事会成员。摩西博士是ABIM的董事会成员，并获得内分泌学和代谢方面的亚专科认证，并且是美国医师协会的会员。自2018年以来，摩西博士目前担任BioFabusa董事会成员。在此之前，Moses博士于2008年至2018年担任Novo NordiskA/SCPH:Novo-B的全球首席医疗官，他于2004年加入该公司。摩西博士于2002年至2006年担任哈佛医学院的医学教授，并与麻省理工学院合作，共同创立并共同指导了临床研究者培训计划，该计划专注于培训转化研究方面的医师-科学家。从1998年到2004年，Moses博士曾担任乔斯林糖尿病中心的高级副总裁兼首席医疗官。摩西博士拥有北卡罗来纳州杜克大学的学士学位和密苏里州华盛顿大学医学院的医学博士学位。
- Alan Moses,has served as a director of the Company since October 2020. Dr. Moses has been a Board member of Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) since March 2021. Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S from 2013 until his retirement in 2018. Prior to that he served in various roles at Novo Nordisk A/S since 2004, beginning as Associate Vice President of Medical Affairs in the United States. Throughout his career, Dr. Moses has specialized in developing novel therapeutics and diagnostics for diabetes mellitus. He co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic, and has served as a member of the Board of Joslin Diabetes Center since December 2021. Dr. Moses also serves on two nonprofit boards as Chairman of the Board of the diaTribe Foundation and as a member of the Greater New England Chapter of the Juvenile Diabetes Research Association. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School.
- Neil Cohen
-
Neil Cohen自2020年4月起担任我们前身为Anchiano TherapeuticsLtd.的董事会成员，并于2020年10月至合并完成之前担任我们的临时首席执行官。Cohen自2012年1月起担任Castel Partners Ltd.董事长兼首席执行官。1994年，他共同创立了领先的风险投资公司Israel Seed Partners，并管理该公司至2019年。科恩先生曾投资并服务于许多私人技术公司的董事会，包括大量被收购或成功完成首次公开募股的公司，包括Compugen Nasdaq:CGEN，Shopping.com（Nasdaq:Shop，被eBay收购），Broadlight（被Broadcom收购，纳斯达克股票代码:AVGO）和Cyota（被RSA收购）。他是以色列中间市场私募股权公司Sky，以色列早期风险投资基金Hetz Ventures Management Ltd.和Shavit Capital的风险合伙人。科恩先生先前是《耶路撒冷邮报》的业务编辑，并在伦敦N M Rothschild&Sons Limited的私募股权集团开始其职业生涯。科恩先生获得牛津大学东方研究学士和硕士学位，并获得一等荣誉。
Neil Cohen has served as a member of our formerly known as Anchiano Therapeutics Ltd. board of directors since April 2020 and served as our interim Chief Executive Officer from October 2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994 he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University. - Neil Cohen自2020年4月起担任我们前身为Anchiano TherapeuticsLtd.的董事会成员，并于2020年10月至合并完成之前担任我们的临时首席执行官。Cohen自2012年1月起担任Castel Partners Ltd.董事长兼首席执行官。1994年，他共同创立了领先的风险投资公司Israel Seed Partners，并管理该公司至2019年。科恩先生曾投资并服务于许多私人技术公司的董事会，包括大量被收购或成功完成首次公开募股的公司，包括Compugen Nasdaq:CGEN，Shopping.com（Nasdaq:Shop，被eBay收购），Broadlight（被Broadcom收购，纳斯达克股票代码:AVGO）和Cyota（被RSA收购）。他是以色列中间市场私募股权公司Sky，以色列早期风险投资基金Hetz Ventures Management Ltd.和Shavit Capital的风险合伙人。科恩先生先前是《耶路撒冷邮报》的业务编辑，并在伦敦N M Rothschild&Sons Limited的私募股权集团开始其职业生涯。科恩先生获得牛津大学东方研究学士和硕士学位，并获得一等荣誉。
- Neil Cohen has served as a member of our formerly known as Anchiano Therapeutics Ltd. board of directors since April 2020 and served as our interim Chief Executive Officer from October 2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994 he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University.
- Adi Mor
-
Adi Mor是Chemomab Ltd.的联合创始人，自2011年成立以来一直担任Chemomab Ltd.的首席执行官，首席科学官和Chemomab Ltd.的董事会成员，直到2021年3月16日合并完成，合并，并在合并后继续为我们公司担任这些职务。Mor博士在免疫学方面拥有深入的知识，专注于罕见疾病，并在设计，开发和申请专利以治疗炎性和纤维化疾病的新型单克隆抗体方面拥有广泛的经验。Mor博士在以色列特拉维夫大学神经生物化学系获得免疫学博士学位，并且是免疫学和炎症性疾病领域众多科学期刊出版物的主要作者。
Adi Mor is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.'s Chief Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.'s board of directors from its formation in 2011 until the Merger, and continued to serve in those capacities for our company thereafter. Dr. Mor's tenure as the Company's Chief Executive Officer concluded simultaneous with the approval of Dr. Dale Pfost's employment by the Company's shareholders on October 25 2021. Dr. Mor has in-depth knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders. - Adi Mor是Chemomab Ltd.的联合创始人，自2011年成立以来一直担任Chemomab Ltd.的首席执行官，首席科学官和Chemomab Ltd.的董事会成员，直到2021年3月16日合并完成，合并，并在合并后继续为我们公司担任这些职务。Mor博士在免疫学方面拥有深入的知识，专注于罕见疾病，并在设计，开发和申请专利以治疗炎性和纤维化疾病的新型单克隆抗体方面拥有广泛的经验。Mor博士在以色列特拉维夫大学神经生物化学系获得免疫学博士学位，并且是免疫学和炎症性疾病领域众多科学期刊出版物的主要作者。
- Adi Mor is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.'s Chief Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.'s board of directors from its formation in 2011 until the Merger, and continued to serve in those capacities for our company thereafter. Dr. Mor's tenure as the Company's Chief Executive Officer concluded simultaneous with the approval of Dr. Dale Pfost's employment by the Company's shareholders on October 25 2021. Dr. Mor has in-depth knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.
- Dale Pfost
-
Dale Pfost自2021年10月25日起担任我们的首席执行官和董事会成员。Pfost博士拥有35年的企业家、投资者和业务主管经验。自2019年以来，Pfost博士一直担任Lodo Therapeutics Corporation的首席执行官兼董事会主席。从2009年到2019年，Pfost博士在他共同创立的公司Microbiome Therapeutics，LLC担任过各种职务，包括从2009年到2010年以及从2016年到2019年再次担任董事会成员兼首席执行官。从2010年到2019年，他担任Advent Life Sciences的普通合伙人。从2013年到2017年，Pfost博士在Vestagen Protective Technologies担任过各种职务，包括2013年至2017年的董事长，执行主席和2015年至2016年的首席执行官。在此之前，Pfost博士在以下公司担任过多个执行职位:2008年至2009年Receptor BioLogix Inc.的首席执行官，Acuity Pharmaceuticals，Inc.的总裁，首席执行官兼董事长（2003年至2007年），Orchid Biosciences的总裁，首席执行官兼董事长，Inc.（从1996年到2002年），担任Oxford GlycoSciences Ltd.的总裁、首席执行官和董事总经理（从1988年到1996年），以及SmithKline Beckman的机器人和自动化化学系统总监（从1984年到1988年）。除了上述内容，Pfost博士还曾在多家公司的董事会任职，包括BioElectronica Corp.，Axosim，Inc.，JMB Companies LLC，Aura Bioscience，Louisiana Bio和CN Creative。Pfost博士在圣巴巴拉加州大学获得学士学位，并在布朗大学获得物理学博士学位。
Dale Pfost has served as our Chief Executive Officer and a member of our board of directors since October 25 2021. Dr. Pfost has 35 years of experience as an entrepreneur, investor and business executive. Since 2019 Dr. Pfost has served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019 Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019 he served as a General Partner at Advent Life Sciences. From 2013 until 2017 Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017 and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. from 2008 until 2009 President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from 1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University. - Dale Pfost自2021年10月25日起担任我们的首席执行官和董事会成员。Pfost博士拥有35年的企业家、投资者和业务主管经验。自2019年以来，Pfost博士一直担任Lodo Therapeutics Corporation的首席执行官兼董事会主席。从2009年到2019年，Pfost博士在他共同创立的公司Microbiome Therapeutics，LLC担任过各种职务，包括从2009年到2010年以及从2016年到2019年再次担任董事会成员兼首席执行官。从2010年到2019年，他担任Advent Life Sciences的普通合伙人。从2013年到2017年，Pfost博士在Vestagen Protective Technologies担任过各种职务，包括2013年至2017年的董事长，执行主席和2015年至2016年的首席执行官。在此之前，Pfost博士在以下公司担任过多个执行职位:2008年至2009年Receptor BioLogix Inc.的首席执行官，Acuity Pharmaceuticals，Inc.的总裁，首席执行官兼董事长（2003年至2007年），Orchid Biosciences的总裁，首席执行官兼董事长，Inc.（从1996年到2002年），担任Oxford GlycoSciences Ltd.的总裁、首席执行官和董事总经理（从1988年到1996年），以及SmithKline Beckman的机器人和自动化化学系统总监（从1984年到1988年）。除了上述内容，Pfost博士还曾在多家公司的董事会任职，包括BioElectronica Corp.，Axosim，Inc.，JMB Companies LLC，Aura Bioscience，Louisiana Bio和CN Creative。Pfost博士在圣巴巴拉加州大学获得学士学位，并在布朗大学获得物理学博士学位。
- Dale Pfost has served as our Chief Executive Officer and a member of our board of directors since October 25 2021. Dr. Pfost has 35 years of experience as an entrepreneur, investor and business executive. Since 2019 Dr. Pfost has served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019 Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019 he served as a General Partner at Advent Life Sciences. From 2013 until 2017 Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017 and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. from 2008 until 2009 President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from 1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University.
- Joel Maryles
-
Joel Maryles， 2014年1月起，他担任我公司董事会成员。过去30年间，他在金融界担任多个高级职位。2007至2012年，他担任本人成立的股票对冲基金T-Cubed Investments LP的投资组合经理；1996至2006年，担任Citigroup Investment Banking的总经理和高级技术银行家，成立并管理了以色列投资银行Citigroup/Salomon Smith Barney；1986至1996年，在美国投资银行Furman Selz担任多职担任，包括以色列技术与保健交易总经理。加入Furman Selz前，他担任First Chicago Investment Advisors的投资官。他在伊利诺伊大学（University of Illinois）获得工程学学士学位，在芝加哥大学（University of Chicago）获得工商管理学硕士学位。
Joel Maryles has served on our board of directors since March 16 2021. Mr. Maryles currently serves on the board of directors and as the Chairman of Remuneration Committee of Jefferies International Ltd., since 2016. Mr. Maryles previously served on the board of directors of Radware Ltd. NASDAQ: RDWR, from 2014 to 2020 and from 2014 to 2016 on the board of directors of EZchip Semiconductor Ltd., which was acquired by Mellanox Technologies in 2016. From 2015 to 2018 Mr. Maryles was a Partner at OurCrowd and from 2007 to 2012 he served as a Portfolio Manager at T-Cubed Investments, which he founded. Prior to that, Mr. Maryles served as a Managing Director in the Investment Banking division of Citigroup, Israel and of Furman Selz. Mr. Maryles holds a Bachelor of Science in Mechanical Engineering from the University of Illinois and an MBA from the University of Chicago, Illinois. - Joel Maryles， 2014年1月起，他担任我公司董事会成员。过去30年间，他在金融界担任多个高级职位。2007至2012年，他担任本人成立的股票对冲基金T-Cubed Investments LP的投资组合经理；1996至2006年，担任Citigroup Investment Banking的总经理和高级技术银行家，成立并管理了以色列投资银行Citigroup/Salomon Smith Barney；1986至1996年，在美国投资银行Furman Selz担任多职担任，包括以色列技术与保健交易总经理。加入Furman Selz前，他担任First Chicago Investment Advisors的投资官。他在伊利诺伊大学（University of Illinois）获得工程学学士学位，在芝加哥大学（University of Chicago）获得工商管理学硕士学位。
- Joel Maryles has served on our board of directors since March 16 2021. Mr. Maryles currently serves on the board of directors and as the Chairman of Remuneration Committee of Jefferies International Ltd., since 2016. Mr. Maryles previously served on the board of directors of Radware Ltd. NASDAQ: RDWR, from 2014 to 2020 and from 2014 to 2016 on the board of directors of EZchip Semiconductor Ltd., which was acquired by Mellanox Technologies in 2016. From 2015 to 2018 Mr. Maryles was a Partner at OurCrowd and from 2007 to 2012 he served as a Portfolio Manager at T-Cubed Investments, which he founded. Prior to that, Mr. Maryles served as a Managing Director in the Investment Banking division of Citigroup, Israel and of Furman Selz. Mr. Maryles holds a Bachelor of Science in Mechanical Engineering from the University of Illinois and an MBA from the University of Chicago, Illinois.
高管简历
中英对照 | 中文 | 英文- Adi Mor
Adi Mor是Chemomab Ltd.的联合创始人，自2011年成立以来一直担任Chemomab Ltd.的首席执行官，首席科学官和Chemomab Ltd.的董事会成员，直到2021年3月16日合并完成，合并，并在合并后继续为我们公司担任这些职务。Mor博士在免疫学方面拥有深入的知识，专注于罕见疾病，并在设计，开发和申请专利以治疗炎性和纤维化疾病的新型单克隆抗体方面拥有广泛的经验。Mor博士在以色列特拉维夫大学神经生物化学系获得免疫学博士学位，并且是免疫学和炎症性疾病领域众多科学期刊出版物的主要作者。
Adi Mor is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.'s Chief Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.'s board of directors from its formation in 2011 until the Merger, and continued to serve in those capacities for our company thereafter. Dr. Mor's tenure as the Company's Chief Executive Officer concluded simultaneous with the approval of Dr. Dale Pfost's employment by the Company's shareholders on October 25 2021. Dr. Mor has in-depth knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.- Adi Mor是Chemomab Ltd.的联合创始人，自2011年成立以来一直担任Chemomab Ltd.的首席执行官，首席科学官和Chemomab Ltd.的董事会成员，直到2021年3月16日合并完成，合并，并在合并后继续为我们公司担任这些职务。Mor博士在免疫学方面拥有深入的知识，专注于罕见疾病，并在设计，开发和申请专利以治疗炎性和纤维化疾病的新型单克隆抗体方面拥有广泛的经验。Mor博士在以色列特拉维夫大学神经生物化学系获得免疫学博士学位，并且是免疫学和炎症性疾病领域众多科学期刊出版物的主要作者。
- Adi Mor is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.'s Chief Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.'s board of directors from its formation in 2011 until the Merger, and continued to serve in those capacities for our company thereafter. Dr. Mor's tenure as the Company's Chief Executive Officer concluded simultaneous with the approval of Dr. Dale Pfost's employment by the Company's shareholders on October 25 2021. Dr. Mor has in-depth knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.
- Arnon Aharon
Arnon Aharon自2018年1月起担任Chemomab Ltd.的首席医疗官，并在合并后继续担任BioLineRx Ltd.的职务。在晋升之前，他曾担任Chemomab的临床开发主管（2016年12月至2017年12月）。加入Chemomab之前，从2014年1月到2016年11月，他担任BioLineRx Ltd.（一家在纳斯达克和特拉维夫证券交易所上市的公司）的首席医疗官，在那里他指导肿瘤和免疫学管道。他还担任生物技术公司的多个高级管理职位，包括在纳斯达克和特拉维夫证券交易所上市的Pharmos Ltd.、Thrombotech Ltd.和LycoRed Ltd.。他是几个行业咨询集团的成员，并为生物技术公司和学术机构提供咨询服务。他获得以色列特拉维夫大学（University of Tel Aviv）的医学博士学位。
Arnon Aharon served as Chemomab Ltd.'s Chief Medical Officer from January 2018 until the Merger and continued in that capacity for our company following the Merger. On November 29 2021 Dr. Aharon notified the Company of his resignation as our Chief Medical Officer, which resignation will enter into effect on February 1 2022. Prior to his position with Chemomab, Dr. Aharon served as Chemomab's Head of Clinical Development from December 2016 to December 2017. Prior to joining Chemomab, from January 2014 to November 2016 Dr. Aharon served as Chief Medical Officer at BioLineRx Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, where he directed the oncology and immunology pipeline. Dr. Aharon also served at multiple senior management positions at biotechnology companies, including Pharmos Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, Thrombotech Ltd., and LycoRed Ltd. Dr. Aharon is a member of several industry advisory groups and provides consulting services to biotechnology companies and academic institutions. Dr. Aharon received his M.D. from the University of Tel Aviv in Israel.- Arnon Aharon自2018年1月起担任Chemomab Ltd.的首席医疗官，并在合并后继续担任BioLineRx Ltd.的职务。在晋升之前，他曾担任Chemomab的临床开发主管（2016年12月至2017年12月）。加入Chemomab之前，从2014年1月到2016年11月，他担任BioLineRx Ltd.（一家在纳斯达克和特拉维夫证券交易所上市的公司）的首席医疗官，在那里他指导肿瘤和免疫学管道。他还担任生物技术公司的多个高级管理职位，包括在纳斯达克和特拉维夫证券交易所上市的Pharmos Ltd.、Thrombotech Ltd.和LycoRed Ltd.。他是几个行业咨询集团的成员，并为生物技术公司和学术机构提供咨询服务。他获得以色列特拉维夫大学（University of Tel Aviv）的医学博士学位。
- Arnon Aharon served as Chemomab Ltd.'s Chief Medical Officer from January 2018 until the Merger and continued in that capacity for our company following the Merger. On November 29 2021 Dr. Aharon notified the Company of his resignation as our Chief Medical Officer, which resignation will enter into effect on February 1 2022. Prior to his position with Chemomab, Dr. Aharon served as Chemomab's Head of Clinical Development from December 2016 to December 2017. Prior to joining Chemomab, from January 2014 to November 2016 Dr. Aharon served as Chief Medical Officer at BioLineRx Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, where he directed the oncology and immunology pipeline. Dr. Aharon also served at multiple senior management positions at biotechnology companies, including Pharmos Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, Thrombotech Ltd., and LycoRed Ltd. Dr. Aharon is a member of several industry advisory groups and provides consulting services to biotechnology companies and academic institutions. Dr. Aharon received his M.D. from the University of Tel Aviv in Israel.
- Dale Pfost
Dale Pfost自2021年10月25日起担任我们的首席执行官和董事会成员。Pfost博士拥有35年的企业家、投资者和业务主管经验。自2019年以来，Pfost博士一直担任Lodo Therapeutics Corporation的首席执行官兼董事会主席。从2009年到2019年，Pfost博士在他共同创立的公司Microbiome Therapeutics，LLC担任过各种职务，包括从2009年到2010年以及从2016年到2019年再次担任董事会成员兼首席执行官。从2010年到2019年，他担任Advent Life Sciences的普通合伙人。从2013年到2017年，Pfost博士在Vestagen Protective Technologies担任过各种职务，包括2013年至2017年的董事长，执行主席和2015年至2016年的首席执行官。在此之前，Pfost博士在以下公司担任过多个执行职位:2008年至2009年Receptor BioLogix Inc.的首席执行官，Acuity Pharmaceuticals，Inc.的总裁，首席执行官兼董事长（2003年至2007年），Orchid Biosciences的总裁，首席执行官兼董事长，Inc.（从1996年到2002年），担任Oxford GlycoSciences Ltd.的总裁、首席执行官和董事总经理（从1988年到1996年），以及SmithKline Beckman的机器人和自动化化学系统总监（从1984年到1988年）。除了上述内容，Pfost博士还曾在多家公司的董事会任职，包括BioElectronica Corp.，Axosim，Inc.，JMB Companies LLC，Aura Bioscience，Louisiana Bio和CN Creative。Pfost博士在圣巴巴拉加州大学获得学士学位，并在布朗大学获得物理学博士学位。
Dale Pfost has served as our Chief Executive Officer and a member of our board of directors since October 25 2021. Dr. Pfost has 35 years of experience as an entrepreneur, investor and business executive. Since 2019 Dr. Pfost has served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019 Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019 he served as a General Partner at Advent Life Sciences. From 2013 until 2017 Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017 and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. from 2008 until 2009 President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from 1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University.- Dale Pfost自2021年10月25日起担任我们的首席执行官和董事会成员。Pfost博士拥有35年的企业家、投资者和业务主管经验。自2019年以来，Pfost博士一直担任Lodo Therapeutics Corporation的首席执行官兼董事会主席。从2009年到2019年，Pfost博士在他共同创立的公司Microbiome Therapeutics，LLC担任过各种职务，包括从2009年到2010年以及从2016年到2019年再次担任董事会成员兼首席执行官。从2010年到2019年，他担任Advent Life Sciences的普通合伙人。从2013年到2017年，Pfost博士在Vestagen Protective Technologies担任过各种职务，包括2013年至2017年的董事长，执行主席和2015年至2016年的首席执行官。在此之前，Pfost博士在以下公司担任过多个执行职位:2008年至2009年Receptor BioLogix Inc.的首席执行官，Acuity Pharmaceuticals，Inc.的总裁，首席执行官兼董事长（2003年至2007年），Orchid Biosciences的总裁，首席执行官兼董事长，Inc.（从1996年到2002年），担任Oxford GlycoSciences Ltd.的总裁、首席执行官和董事总经理（从1988年到1996年），以及SmithKline Beckman的机器人和自动化化学系统总监（从1984年到1988年）。除了上述内容，Pfost博士还曾在多家公司的董事会任职，包括BioElectronica Corp.，Axosim，Inc.，JMB Companies LLC，Aura Bioscience，Louisiana Bio和CN Creative。Pfost博士在圣巴巴拉加州大学获得学士学位，并在布朗大学获得物理学博士学位。
- Dale Pfost has served as our Chief Executive Officer and a member of our board of directors since October 25 2021. Dr. Pfost has 35 years of experience as an entrepreneur, investor and business executive. Since 2019 Dr. Pfost has served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019 Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019 he served as a General Partner at Advent Life Sciences. From 2013 until 2017 Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017 and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. from 2008 until 2009 President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from 1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University.
- Donald Marvin
Donald Marvin自2021年11月8日起担任我们的首席财务官，执行副总裁兼首席运营官。Marvin先生在成长型企业拥有超过35年的经验，涉及企业融资和筹资、战略、企业发展、并购和运营。2020年至2021年，Marvin先生担任Lodo Therapeutics的执行副总裁兼首席财务官。2014年至2021年，他曾担任Concentric的董事长，总裁兼首席执行官。在Concentric任职之前，从2006年到2014年，Marvin先生担任Cairn Associates的管理合伙人。他曾担任Identigen公司的总裁兼首席执行官（从2006年到2009年）。他曾担任Orchid Biosciences公司的联席Founder，在那里他曾担任首席运营官、首席财务官和公司发展高级副总裁（从1997年到2003年），以及Diatron Corporation的总裁兼首席执行官（从1986年到1994年）。在职业生涯的早期，Marvin先生在雅培，勃林格殷格翰，拜耳和百事可乐担任越来越重要的职位。Marvin先生获得了俄亥俄州立大学的理学学士学位和爱奥那学院的工商管理硕士学位。
Donald Marvin has served as our Chief Financial Officer, Executive Vice President and Chief Operating Officer since November 8 2021. Mr. Marvin has more than 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations. Mr. Marvin served as Executive Vice President and Chief Financial Officer of Lodo Therapeutics from 2020 until 2021. He was previously Chairman, President and CEO of Concentric from 2014 to 2021. Prior to his positions at Concentric, Mr. Marvin was Managing Partner of Cairn Associates from 2006 until 2014. He was President and CEO of IdentiGEN from 2006 until 2009. Mr. Marvin was a co-founder of Orchid BioSciences, where he served as Chief Operating Officer, CFO and Senior Vice President of Corporate Development from 1997 to 2003 and President and Chief Executive Officer of Diatron Corporation from 1986 until 1994. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer Ingelheim, Bayer, and PepsiCo. Mr. Marvin earned a Bachelor of Science degree from The Ohio State University and an MBA from Iona College.- Donald Marvin自2021年11月8日起担任我们的首席财务官，执行副总裁兼首席运营官。Marvin先生在成长型企业拥有超过35年的经验，涉及企业融资和筹资、战略、企业发展、并购和运营。2020年至2021年，Marvin先生担任Lodo Therapeutics的执行副总裁兼首席财务官。2014年至2021年，他曾担任Concentric的董事长，总裁兼首席执行官。在Concentric任职之前，从2006年到2014年，Marvin先生担任Cairn Associates的管理合伙人。他曾担任Identigen公司的总裁兼首席执行官（从2006年到2009年）。他曾担任Orchid Biosciences公司的联席Founder，在那里他曾担任首席运营官、首席财务官和公司发展高级副总裁（从1997年到2003年），以及Diatron Corporation的总裁兼首席执行官（从1986年到1994年）。在职业生涯的早期，Marvin先生在雅培，勃林格殷格翰，拜耳和百事可乐担任越来越重要的职位。Marvin先生获得了俄亥俄州立大学的理学学士学位和爱奥那学院的工商管理硕士学位。
- Donald Marvin has served as our Chief Financial Officer, Executive Vice President and Chief Operating Officer since November 8 2021. Mr. Marvin has more than 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations. Mr. Marvin served as Executive Vice President and Chief Financial Officer of Lodo Therapeutics from 2020 until 2021. He was previously Chairman, President and CEO of Concentric from 2014 to 2021. Prior to his positions at Concentric, Mr. Marvin was Managing Partner of Cairn Associates from 2006 until 2014. He was President and CEO of IdentiGEN from 2006 until 2009. Mr. Marvin was a co-founder of Orchid BioSciences, where he served as Chief Operating Officer, CFO and Senior Vice President of Corporate Development from 1997 to 2003 and President and Chief Executive Officer of Diatron Corporation from 1986 until 1994. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer Ingelheim, Bayer, and PepsiCo. Mr. Marvin earned a Bachelor of Science degree from The Ohio State University and an MBA from Iona College.